US4634665A
(en)
|
1980-02-25 |
1987-01-06 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
US4399216A
(en)
|
1980-02-25 |
1983-08-16 |
The Trustees Of Columbia University |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
US5179017A
(en)
|
1980-02-25 |
1993-01-12 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
EP0154316B1
(en)
|
1984-03-06 |
1989-09-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified lymphokine and production thereof
|
US5374548A
(en)
|
1986-05-02 |
1994-12-20 |
Genentech, Inc. |
Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
|
MX9203291A
(es)
|
1985-06-26 |
1992-08-01 |
Liposome Co Inc |
Metodo para acoplamiento de liposomas.
|
GB8601597D0
(en)
|
1986-01-23 |
1986-02-26 |
Wilson R H |
Nucleotide sequences
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
US5260203A
(en)
|
1986-09-02 |
1993-11-09 |
Enzon, Inc. |
Single polypeptide chain binding molecules
|
US4881175A
(en)
|
1986-09-02 |
1989-11-14 |
Genex Corporation |
Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
|
WO1988007089A1
(en)
|
1987-03-18 |
1988-09-22 |
Medical Research Council |
Altered antibodies
|
US5013653A
(en)
|
1987-03-20 |
1991-05-07 |
Creative Biomolecules, Inc. |
Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
|
US5132405A
(en)
|
1987-05-21 |
1992-07-21 |
Creative Biomolecules, Inc. |
Biosynthetic antibody binding sites
|
US5258498A
(en)
|
1987-05-21 |
1993-11-02 |
Creative Biomolecules, Inc. |
Polypeptide linkers for production of biosynthetic proteins
|
JPH02500329A
(ja)
|
1987-05-21 |
1990-02-08 |
クリエイテイブ・バイオマリキユールズ・インコーポレーテツド |
ターゲット化多機能蛋白質
|
US5091513A
(en)
|
1987-05-21 |
1992-02-25 |
Creative Biomolecules, Inc. |
Biosynthetic antibody binding sites
|
GB8717430D0
(en)
|
1987-07-23 |
1987-08-26 |
Celltech Ltd |
Recombinant dna product
|
US5804381A
(en)
|
1996-10-03 |
1998-09-08 |
Cornell Research Foundation |
Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
|
GB8809129D0
(en)
|
1988-04-18 |
1988-05-18 |
Celltech Ltd |
Recombinant dna methods vectors and host cells
|
US5476996A
(en)
|
1988-06-14 |
1995-12-19 |
Lidak Pharmaceuticals |
Human immune system in non-human animal
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
CA2006596C
(en)
|
1988-12-22 |
2000-09-05 |
Rika Ishikawa |
Chemically-modified g-csf
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
US5108921A
(en)
|
1989-04-03 |
1992-04-28 |
Purdue Research Foundation |
Method for enhanced transmembrane transport of exogenous molecules
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6673986B1
(en)
|
1990-01-12 |
2004-01-06 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
ES2087997T3
(es)
|
1990-01-12 |
1996-08-01 |
Cell Genesys Inc |
Generacion de anticuerpos xenogenicos.
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
US6172197B1
(en)
|
1991-07-10 |
2001-01-09 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5789650A
(en)
|
1990-08-29 |
1998-08-04 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
US5874299A
(en)
|
1990-08-29 |
1999-02-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
US6255458B1
(en)
|
1990-08-29 |
2001-07-03 |
Genpharm International |
High affinity human antibodies and human antibodies against digoxin
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US6300129B1
(en)
|
1990-08-29 |
2001-10-09 |
Genpharm International |
Transgenic non-human animals for producing heterologous antibodies
|
US5877397A
(en)
|
1990-08-29 |
1999-03-02 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
JP2938569B2
(ja)
|
1990-08-29 |
1999-08-23 |
ジェンファーム インターナショナル,インコーポレイティド |
異種免疫グロブリンを作る方法及びトランスジェニックマウス
|
US5814318A
(en)
|
1990-08-29 |
1998-09-29 |
Genpharm International Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
US6235525B1
(en)
|
1991-05-23 |
2001-05-22 |
Ludwig Institute For Cancer Research |
Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
|
US5885793A
(en)
|
1991-12-02 |
1999-03-23 |
Medical Research Council |
Production of anti-self antibodies from antibody segment repertoires and displayed on phage
|
CA2124967C
(en)
|
1991-12-17 |
2008-04-08 |
Nils Lonberg |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
US5620886A
(en)
|
1993-03-18 |
1997-04-15 |
Ludwig Institute For Cancer Research |
Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
|
JPH08509612A
(ja)
|
1993-04-26 |
1996-10-15 |
ジェンファーム インターナショナル インコーポレイテッド |
異種抗体を産生することができるトランスジェニック非ヒト動物
|
AU691811B2
(en)
|
1993-06-16 |
1998-05-28 |
Celltech Therapeutics Limited |
Antibodies
|
US5821332A
(en)
|
1993-11-03 |
1998-10-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Receptor on the surface of activated CD4+ T-cells: ACT-4
|
JPH08507549A
(ja)
|
1993-12-27 |
1996-08-13 |
バクスター、インターナショナル、インコーポレイテッド |
水溶性の非免疫原性ポリアミド架橋剤
|
US5759546A
(en)
|
1994-02-04 |
1998-06-02 |
Weinberg; Andrew D. |
Treatment of CD4 T-cell mediated conditions
|
US6242566B1
(en)
|
1994-02-10 |
2001-06-05 |
Board Of Trustees Of The Leland Stanford Junior University |
Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US6410690B1
(en)
|
1995-06-07 |
2002-06-25 |
Medarex, Inc. |
Therapeutic compounds comprised of anti-Fc receptor antibodies
|
US5811097A
(en)
|
1995-07-25 |
1998-09-22 |
The Regents Of The University Of California |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
EP0862553A4
(en)
|
1995-10-03 |
1999-02-03 |
Scripps Research Inst |
CBI ANALOG OF CC-1065 AND THE DUOCARMYCINES
|
ATE279947T1
(de)
|
1996-03-18 |
2004-11-15 |
Univ Texas |
Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
|
US5834597A
(en)
|
1996-05-20 |
1998-11-10 |
Protein Design Labs, Inc. |
Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
|
US5922845A
(en)
|
1996-07-11 |
1999-07-13 |
Medarex, Inc. |
Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
|
US6069233A
(en)
|
1996-10-03 |
2000-05-30 |
Memorial Sloan-Kettering Cancer Center |
Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
JP2001523958A
(ja)
|
1997-03-21 |
2001-11-27 |
ブライハム アンド ウィミンズ ホスピタル,インコーポレイテッド |
免疫療法のctla−4結合ペプチド
|
DE69833755T2
(de)
|
1997-05-21 |
2006-12-28 |
Biovation Ltd. |
Verfahren zur herstellung von nicht-immunogenen proteinen
|
US6312700B1
(en)
*
|
1998-02-24 |
2001-11-06 |
Andrew D. Weinberg |
Method for enhancing an antigen specific immune response with OX-40L
|
DE69939526D1
(de)
|
1998-02-24 |
2008-10-23 |
Sisters Of Providence In Orego |
Zusammensetzungen, die entweder ein ox-40-rezeptor-bindemittel oder eine für ein solches bindemittel kodierende nukleicsäuresequenz enthalten, und verfahren zur verbesserung der antigenspezifischen immunantwort
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
ES2292236T3
(es)
|
1998-04-02 |
2008-03-01 |
Genentech, Inc. |
Variantes de anticuerpos y sus fragmentos.
|
ES2434961T5
(es)
|
1998-04-20 |
2018-01-18 |
Roche Glycart Ag |
Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
AU772676B2
(en)
|
1998-12-23 |
2004-05-06 |
Amgen Fremont Inc. |
Human monoclonal antibodies to CTLA-4
|
EP2386574A3
(en)
|
1999-01-15 |
2012-06-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
DK1914244T3
(da)
|
1999-04-09 |
2013-07-22 |
Kyowa Hakko Kirin Co Ltd |
Fremgangsmåde til at modulere aktiviteten af funktionelle immunmolekyler.
|
JP4118462B2
(ja)
|
1999-07-19 |
2008-07-16 |
株式会社リコー |
携帯電子機器
|
EP1074563A1
(en)
|
1999-08-02 |
2001-02-07 |
F. Hoffmann-La Roche Ag |
Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof
|
ATE353365T1
(de)
|
1999-08-23 |
2007-02-15 |
Dana Farber Cancer Inst Inc |
Neue b7-4 moleküle und deren verwendungen
|
IL148079A0
(en)
|
1999-08-24 |
2002-09-12 |
Medarex Inc |
Human ctla-4 antibodies and compositions containing the same
|
ATE342962T1
(de)
|
1999-08-25 |
2006-11-15 |
Immunex Corp |
Zusammensetzungen und verfahren für verbesserte zellkultur
|
US6774226B1
(en)
|
1999-11-30 |
2004-08-10 |
Ludwig Institute For Cancer Research |
Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
|
EP1234031B2
(en)
|
1999-11-30 |
2021-11-24 |
Mayo Foundation For Medical Education And Research |
B7-h1, a novel immunoregulatory molecule
|
WO2001058957A2
(en)
|
2000-02-11 |
2001-08-16 |
Lexigen Pharmaceuticals Corp. |
Enhancing the circulating half-life of antibody-based fusion proteins
|
AU2001249727A1
(en)
|
2000-03-31 |
2001-10-15 |
Genentech, Inc. |
Compositions and methods for detecting and quantifying gene expression
|
TWI313299B
(en)
|
2000-11-30 |
2009-08-11 |
Medarex Inc |
Transgenic transchromosomal rodents for making human antibodies
|
JP4336498B2
(ja)
|
2000-12-12 |
2009-09-30 |
メディミューン,エルエルシー |
延長した半減期を有する分子ならびにその組成物および用途
|
US6794501B2
(en)
|
2001-05-04 |
2004-09-21 |
Ludwig Institute For Cancer Research |
Colon cancer antigen panel
|
EP1421203A4
(en)
|
2001-05-17 |
2005-06-01 |
Diversa Corp |
NEW ANTIGEN-BINDING MOLECULES FOR THERAPEUTIC, DIAGNOSTIC, PROPHYLACTIC, ENZYMATIC, INDUSTRIAL AND AGRICULTURAL APPLICATIONS AND METHOD FOR THE PRODUCTION AND SCREENING THEREOF
|
ITMI20011465A1
(it)
|
2001-07-10 |
2003-01-10 |
Novuspharma Spa |
Gene ad attivita' oncosoppressiva
|
WO2003035835A2
(en)
|
2001-10-25 |
2003-05-01 |
Genentech, Inc. |
Glycoprotein compositions
|
US20040002587A1
(en)
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
US20040110226A1
(en)
|
2002-03-01 |
2004-06-10 |
Xencor |
Antibody optimization
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US20040014194A1
(en)
|
2002-03-27 |
2004-01-22 |
Schering Corporation |
Beta-secretase crystals and methods for preparing and using the same
|
IL149820A0
(en)
|
2002-05-23 |
2002-11-10 |
Curetech Ltd |
Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
|
NZ536746A
(en)
|
2002-06-13 |
2007-02-23 |
Crucell Holland Bv |
An agonistic antibody or fragment thereof that immunospecifically binds and stimulates the human OX40-receptor
|
WO2004016750A2
(en)
|
2002-08-14 |
2004-02-26 |
Macrogenics, Inc. |
FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
|
DK2364996T3
(en)
|
2002-09-27 |
2017-02-06 |
Xencor Inc |
Optimized Fc variants and methods for their formation
|
SI1562972T1
(sl)
|
2002-10-15 |
2010-12-31 |
Facet Biotech Corp |
ALTERACIJA FcRn VEZANIH AFINITET ALI SERUMSKIH RAZPOLOVNIH DOB ANTITELESC Z MUTAGENEZO
|
JP2006516094A
(ja)
|
2002-11-08 |
2006-06-22 |
ジェネンテック・インコーポレーテッド |
ナチュラルキラー細胞関連疾患の治療のための組成物と方法
|
EP1587540B1
(en)
|
2003-01-09 |
2021-09-15 |
MacroGenics, Inc. |
IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
|
US20040197312A1
(en)
|
2003-04-02 |
2004-10-07 |
Marina Moskalenko |
Cytokine-expressing cellular vaccine combinations
|
WO2004110498A2
(en)
|
2003-05-14 |
2004-12-23 |
Immunogen, Inc. |
Drug conjugate composition
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
WO2004112706A2
(en)
|
2003-06-13 |
2004-12-29 |
The Trustees Of The University Of Pennsylvania |
Vaccines, immunotherapeutics and methods for using the same
|
WO2005044853A2
(en)
|
2003-11-01 |
2005-05-19 |
Genentech, Inc. |
Anti-vegf antibodies
|
US7396914B2
(en)
*
|
2003-08-04 |
2008-07-08 |
University Of Massachusetts |
SARS nucleic acids, proteins, antibodies, and uses thereof
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
GB0324368D0
(en)
|
2003-10-17 |
2003-11-19 |
Univ Cambridge Tech |
Polypeptides including modified constant regions
|
ES2579836T3
(es)
|
2003-11-06 |
2016-08-17 |
Seattle Genetics, Inc. |
Compuestos de monometilvalina capaces de conjugación con ligandos
|
DK1706424T3
(da)
|
2004-01-12 |
2009-11-02 |
Applied Molecular Evolution |
FC-region varianter
|
EP1720908A2
(en)
|
2004-02-17 |
2006-11-15 |
Absalus, Inc. |
Super-humanized antibodies against respiratory syncytial virus
|
EP1737890A2
(en)
|
2004-03-24 |
2007-01-03 |
Xencor, Inc. |
Immunoglobulin variants outside the fc region
|
US7778814B2
(en)
|
2004-03-30 |
2010-08-17 |
Siemens Aktiengesellschaft |
Method and device for simulating an automation system
|
WO2006020114A2
(en)
|
2004-08-04 |
2006-02-23 |
Applied Molecular Evolution, Inc. |
Variant fc regions
|
WO2006029459A1
(en)
*
|
2004-09-13 |
2006-03-23 |
Evogenix, Inc |
Antibodies specific for hepatocellular carcinoma and other carcinomas and uses thereof
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US20090145493A1
(en)
|
2004-11-23 |
2009-06-11 |
Pip Co., Ltd. |
Built-in wall water service box
|
US7700099B2
(en)
|
2005-02-14 |
2010-04-20 |
Merck & Co., Inc. |
Non-immunostimulatory antibody and compositions containing the same
|
EP3153525A1
(en)
*
|
2005-03-23 |
2017-04-12 |
Genmab A/S |
Antibodies against cd38 for treatment of multiple myeloma
|
BRPI0610235B8
(pt)
|
2005-05-09 |
2021-05-25 |
Squibb & Sons Llc |
anticorpos monoclonais geneticamente modificados e diferentes daqueles encontrados na natureza, ou porção de ligação ao antígeno dos mesmos, usos terapêuticos dos mesmos, composições, imunoconjugado, molécula biespecífica compreendendo os mesmos, molécula de ácido nucléico e vetor de expressão
|
KR101562549B1
(ko)
|
2005-05-10 |
2015-10-23 |
인사이트 홀딩스 코포레이션 |
인돌아민 2,3-디옥시게나제의 조절제 및 이의 사용방법
|
US8163881B2
(en)
|
2005-05-31 |
2012-04-24 |
The Board Of Regents Of The University Of Texas System |
Immunoglobulin molecules with improved characteristics
|
UA99701C2
(ru)
|
2005-07-01 |
2012-09-25 |
Медарекс, Инк. |
Человеческое моноклональное антитело, которое специфически связывается с лигандом-1 запрограммированной гибели клеток (pd-l1)
|
WO2007038868A2
(en)
|
2005-10-03 |
2007-04-12 |
The University Of British Columbia |
Novel enediyne compound and uses thereof
|
US20080206246A1
(en)
|
2006-04-05 |
2008-08-28 |
Ravetch Jeffrey V |
Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
|
TWI461436B
(zh)
*
|
2005-11-25 |
2014-11-21 |
Kyowa Hakko Kirin Co Ltd |
人類cd134(ox40)之人類單株抗體及其製造及使用方法
|
NZ594466A
(en)
*
|
2005-12-08 |
2012-08-31 |
Medarex Inc |
Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
|
CA2634198C
(en)
|
2005-12-20 |
2014-06-03 |
Incyte Corporation |
N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
|
WO2007084559A2
(en)
|
2006-01-13 |
2007-07-26 |
Board Of Regents, The University Of Texas System |
Methods to treat disease states by influencing the signaling of ox40-receptors and high throughput screening methods for identifying substances therefor
|
PE20080102A1
(es)
|
2006-05-25 |
2008-02-11 |
Bristol Myers Squibb Co |
Conjugados de analogos de aziridinil-epotilona y composiciones farmaceuticas que comprenden los mismos
|
PE20080316A1
(es)
|
2006-05-25 |
2008-04-10 |
Bristol Myers Squibb Co |
Compuestos de aziridinil-epotilona
|
WO2007149880A2
(en)
|
2006-06-21 |
2007-12-27 |
Genentech, Inc. |
Crystal structure of ox40l and ox40l complexed with ox40 receptor
|
CL2007002650A1
(es)
|
2006-09-19 |
2008-02-08 |
Incyte Corp |
Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
|
EP2064207B1
(en)
|
2006-09-19 |
2013-11-06 |
Incyte Corporation |
N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
|
EP1914242A1
(en)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Novel anti-CD38 antibodies for the treatment of cancer
|
GB0620894D0
(en)
|
2006-10-20 |
2006-11-29 |
Univ Southampton |
Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
|
WO2008140603A2
(en)
|
2006-12-08 |
2008-11-20 |
Macrogenics, Inc. |
METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
|
RU2448979C2
(ru)
|
2006-12-14 |
2012-04-27 |
Ридженерон Фармасьютикалз, Инк. |
Антитела человека к дельта-подобному лиганду-4 человека
|
TWI412367B
(zh)
|
2006-12-28 |
2013-10-21 |
Medarex Llc |
化學鏈接劑與可裂解基質以及其之綴合物
|
CA2679399A1
(en)
|
2007-02-27 |
2008-09-04 |
Genetech, Inc. |
Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
CN101674847A
(zh)
|
2007-05-02 |
2010-03-17 |
弗·哈夫曼-拉罗切有限公司 |
稳定蛋白质的方法
|
CN101687933B
(zh)
|
2007-05-30 |
2015-11-25 |
浦项工科大学校产学协力团 |
免疫球蛋白融合蛋白
|
WO2009014708A2
(en)
|
2007-07-23 |
2009-01-29 |
Cell Genesys, Inc. |
Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
|
DE102007036200A1
(de)
|
2007-08-02 |
2009-02-05 |
Knorr-Bremse Systeme für Nutzfahrzeuge GmbH |
Induktiver Weg- oder Drehwinkelsensor mit zwischen zwei Spulen angeordnetem Abschirmblech
|
US20090304719A1
(en)
|
2007-08-22 |
2009-12-10 |
Patrick Daugherty |
Activatable binding polypeptides and methods of identification and use thereof
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
EP2214700A4
(en)
|
2007-11-02 |
2012-08-22 |
Janssen Biotech Inc |
HALF-SYNTHETIC GLP-1 PEPTIDE FUSION CONSTRUCTS, METHOD AND USES
|
JP5583592B2
(ja)
|
2007-11-30 |
2014-09-03 |
ニューリンク ジェネティクス コーポレイション |
Ido阻害剤
|
US8815237B2
(en)
|
2007-12-05 |
2014-08-26 |
Massachusetts Institute Of Technology |
Aglycosylated immunoglobulin mutants
|
PT2242771E
(pt)
|
2007-12-14 |
2013-08-29 |
Bristol Myers Squibb Co |
Moléculas de ligação ao recetor humano ox40
|
LT2808343T
(lt)
|
2007-12-26 |
2019-09-10 |
Xencor Inc. |
Fc variantai su pakitusiu prisijungimu prie fcrn
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
JP5770624B2
(ja)
|
2008-04-09 |
2015-08-26 |
ジェネンテック, インコーポレイテッド |
免疫関連疾患の治療のための新規組成物と方法
|
CN102089325A
(zh)
|
2008-04-17 |
2011-06-08 |
埃博灵克斯股份有限公司 |
能够结合血清白蛋白的肽,以及包含其的化合物、构建体和多肽
|
US8163551B2
(en)
|
2008-05-02 |
2012-04-24 |
Seattle Genetics, Inc. |
Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
US20100189727A1
(en)
|
2008-12-08 |
2010-07-29 |
Tegopharm Corporation |
Masking Ligands For Reversible Inhibition Of Multivalent Compounds
|
EP4169951A1
(en)
|
2008-12-09 |
2023-04-26 |
F. Hoffmann-La Roche AG |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
MX362028B
(es)
|
2009-02-03 |
2019-01-04 |
Amunix Pharmaceuticals Inc |
Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos.
|
SI2398498T1
(sl)
|
2009-02-17 |
2019-02-28 |
Ucb Biopharma Sprl |
Molekule protiteles, s specifičnostjo za humani OX40
|
US20110007023A1
(en)
|
2009-07-09 |
2011-01-13 |
Sony Ericsson Mobile Communications Ab |
Display device, touch screen device comprising the display device, mobile device and method for sensing a force on a display device
|
US8394922B2
(en)
|
2009-08-03 |
2013-03-12 |
Medarex, Inc. |
Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
|
ES2601226T3
(es)
|
2009-10-28 |
2017-02-14 |
Newlink Genetics Corporation |
Derivados de imidazol como inhibidores de IDO
|
CN104961829B
(zh)
|
2009-11-24 |
2018-08-21 |
米迪缪尼有限公司 |
针对b7-h1的靶向结合剂
|
KR101853702B1
(ko)
|
2009-12-07 |
2018-05-03 |
더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 |
항-종양 항체 치료를 향상시키는 방법
|
SI2510010T1
(sl)
|
2009-12-10 |
2016-02-29 |
F. Hoffmann-La Roche Ag |
Protitelesa, vezavna na ekstracelično domeno 4 humanega csf1r in njihova uporaba
|
MY173363A
(en)
|
2009-12-10 |
2020-01-21 |
Regeneron Pharma |
Mice that make heavy chain antibodies
|
GB201001791D0
(en)
|
2010-02-03 |
2010-03-24 |
Ucb Pharma Sa |
Process for obtaining antibodies
|
US20120021409A1
(en)
|
2010-02-08 |
2012-01-26 |
Regeneron Pharmaceuticals, Inc. |
Common Light Chain Mouse
|
EP2501817B2
(en)
|
2010-02-08 |
2021-04-21 |
Regeneron Pharmaceuticals, Inc. |
Common light chain mouse
|
PT3053932T
(pt)
|
2010-02-19 |
2020-10-21 |
Xencor Inc |
Novas imunoadesinas ctla4-ig
|
CN102892426B
(zh)
|
2010-03-04 |
2016-08-31 |
宏观基因有限公司 |
与b7-h3反应性的抗体、其免疫学活性片段及其用途
|
CA2789071C
(en)
|
2010-03-05 |
2018-03-27 |
F. Hoffmann-La Roche Ag |
Antibodies against human csf-1r and uses thereof
|
KR101656548B1
(ko)
|
2010-03-05 |
2016-09-09 |
에프. 호프만-라 로슈 아게 |
인간 csf-1r에 대한 항체 및 이의 용도
|
ES2623057T3
(es)
|
2010-04-15 |
2017-07-10 |
Medimmune Limited |
Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas
|
BR112012026801B8
(pt)
|
2010-04-15 |
2021-05-25 |
Medimmune Ltd |
conjugados de pirrolobenzodiazepina direcionados, composição farmacêutica, uso dos mesmos para tratamento de uma doença proliferativa ou autoimune e ligante de medicamento
|
US8206715B2
(en)
|
2010-05-04 |
2012-06-26 |
Five Prime Therapeutics, Inc. |
Antibodies that bind colony stimulating factor 1 receptor (CSF1R)
|
MX348942B
(es)
|
2010-06-22 |
2017-07-04 |
Regeneron Pharma |
Ratones que expresan una cadena ligera hibrida de inmunoglobulina.
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
EP2399604A1
(en)
|
2010-06-25 |
2011-12-28 |
F. Hoffmann-La Roche AG |
Novel antibody formulation
|
HUE031371T2
(en)
|
2010-08-23 |
2017-07-28 |
Univ Texas |
Anti-OX40 antibodies and their application procedures
|
MX337040B
(es)
|
2010-09-09 |
2016-02-09 |
Pfizer |
Moleculas de union a 4-1bb.
|
EP2656073A4
(en)
|
2010-12-20 |
2014-12-17 |
Univ Rockefeller |
MODULATION AGONISTIC TNFR ANTIBODY
|
AU2012222252B2
(en)
|
2011-02-25 |
2016-08-25 |
Chugai Seiyaku Kabushiki Kaisha |
FcgammaRIIb-specific Fc antibody
|
SI2697257T1
(sl)
|
2011-04-13 |
2017-02-28 |
Bristol-Myers Squibb Company |
FC fuzijski proteini, ki vsebujejo nove linkerje ali razmestitve
|
NO2694640T3
(zh)
|
2011-04-15 |
2018-03-17 |
|
|
WO2012145493A1
(en)
|
2011-04-20 |
2012-10-26 |
Amplimmune, Inc. |
Antibodies and other molecules that bind b7-h1 and pd-1
|
US8852599B2
(en)
|
2011-05-26 |
2014-10-07 |
Bristol-Myers Squibb Company |
Immunoconjugates, compositions for making them, and methods of making and use
|
JP5708369B2
(ja)
|
2011-08-24 |
2015-04-30 |
コベルコ建機株式会社 |
作業機械
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
WO2013041606A1
(en)
|
2011-09-20 |
2013-03-28 |
Spirogen Sàrl |
Pyrrolobenzodiazepines as unsymmetrical dimeric pbd compounds for inclusion in targeted conjugates
|
US20130149300A1
(en)
|
2011-09-27 |
2013-06-13 |
Icon Genetics Gmbh |
MONOCLONAL ANTIBODIES WITH ALTERED AFFINITIES FOR HUMAN FCyRI, FCyRIIIa, AND C1q PROTEINS
|
ES2808152T3
(es)
|
2011-11-28 |
2021-02-25 |
Merck Patent Gmbh |
Anticuerpos anti-PD-L1 y usos de los mismos
|
CA2853889A1
(en)
|
2011-12-15 |
2013-06-20 |
F. Hoffmann-La Roche Ag |
Antibodies against human csf-1r and uses thereof
|
CN117964709A
(zh)
|
2011-12-19 |
2024-05-03 |
洛克菲勒大学 |
非唾液酸化的抗炎多肽
|
JP6416630B2
(ja)
|
2012-02-06 |
2018-10-31 |
ジェネンテック, インコーポレイテッド |
Csf1r阻害剤を用いるための組成物及び方法
|
WO2013119202A1
(en)
|
2012-02-06 |
2013-08-15 |
Providence Health & Services - Oregon |
Cancer treatment and monitoring methods using ox40 agonists
|
ES2615268T3
(es)
|
2012-02-13 |
2017-06-06 |
Bristol-Myers Squibb Company |
Compuestos de enediino, conjugados de los mismos y usos y métodos para ello
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
KR20150018533A
(ko)
|
2012-05-11 |
2015-02-23 |
파이브 프라임 테라퓨틱스, 인크. |
콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
|
US9212224B2
(en)
|
2012-05-15 |
2015-12-15 |
Bristol-Myers Squibb Company |
Antibodies that bind PD-L1 and uses thereof
|
AR091649A1
(es)
|
2012-07-02 |
2015-02-18 |
Bristol Myers Squibb Co |
Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
|
CN104684582A
(zh)
|
2012-08-31 |
2015-06-03 |
戊瑞治疗有限公司 |
用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
|
RS65556B1
(sr)
|
2012-09-13 |
2024-06-28 |
Bristol Myers Squibb Co |
Proteini domena skele na bazi fibronektina koji vezuju miostatin
|
JP2016500251A
(ja)
|
2012-12-03 |
2016-01-12 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
免疫調節Fc融合タンパク質の抗癌活性の増強
|
US20140242077A1
(en)
|
2013-01-23 |
2014-08-28 |
Abbvie, Inc. |
Methods and compositions for modulating an immune response
|
RS56169B1
(sr)
|
2013-02-14 |
2017-11-30 |
Bristol Myers Squibb Co |
Jedinjenja tubulisina, metode pripreme i primena
|
SI2976361T1
(sl)
*
|
2013-03-18 |
2018-11-30 |
Biocerox Products B.V. |
Humanizirana ANTI-CD134 (OX40) protitelesa in njih uporaba
|
LT3021869T
(lt)
|
2013-07-16 |
2020-10-12 |
F. Hoffmann-La Roche Ag |
Vėžio gydymo būdai, naudojant pd-1 ašį surišančius antagonistus ir tigit inhibitorius
|
AU2014364593A1
(en)
|
2013-12-17 |
2016-07-07 |
Genentech, Inc. |
Methods of treating cancer using PD-1 axis binding antagonists and an anti-CD20 antibody
|
AU2014364606A1
(en)
|
2013-12-17 |
2016-07-07 |
Genentech, Inc. |
Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
WO2015131176A1
(en)
|
2014-02-28 |
2015-09-03 |
Podack Eckhard R |
Compositions, methods, and kits for treatment of cancer
|
RS59738B1
(sr)
|
2014-03-31 |
2020-02-28 |
Hoffmann La Roche |
Anti-ox40 antitela i postupci primene
|
WO2015153514A1
(en)
|
2014-03-31 |
2015-10-08 |
Genentech, Inc. |
Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
|
CA2954446A1
(en)
|
2014-07-09 |
2016-01-14 |
Shanghai Birdie Biotech, Inc. |
Anti-pd-l1 combinations for treating tumors
|
CN105233291A
(zh)
|
2014-07-09 |
2016-01-13 |
博笛生物科技有限公司 |
用于治疗癌症的联合治疗组合物和联合治疗方法
|
CN112546238A
(zh)
|
2014-09-01 |
2021-03-26 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
ES2774448T3
(es)
|
2014-10-03 |
2020-07-21 |
Novartis Ag |
Terapias de combinación
|
TW201619200A
(zh)
|
2014-10-10 |
2016-06-01 |
麥迪紐有限責任公司 |
人類化抗-ox40抗體及其用途
|
EP3206711B1
(en)
|
2014-10-14 |
2023-05-31 |
Novartis AG |
Antibody molecules to pd-l1 and uses thereof
|
US11285194B2
(en)
|
2014-10-24 |
2022-03-29 |
Calidi Biotherapeutics, Inc. |
Combination immunotherapy approach for treatment of cancer
|
US20160160290A1
(en)
|
2014-11-03 |
2016-06-09 |
Genentech, Inc. |
Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
|
WO2016073759A1
(en)
|
2014-11-05 |
2016-05-12 |
The Regents Of The University Of California |
Combination immunotherapy
|
WO2016073282A1
(en)
|
2014-11-06 |
2016-05-12 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and tigit inhibitors
|
JP2017537090A
(ja)
|
2014-11-17 |
2017-12-14 |
ジェネンテック, インコーポレイテッド |
Ox40結合アゴニスト及びpd−1軸結合アンタゴニストを含む併用療法
|
EP3233918A1
(en)
|
2014-12-19 |
2017-10-25 |
Novartis AG |
Combination therapies
|
EA035412B1
(ru)
|
2015-05-29 |
2020-06-10 |
Бристол-Майерс Сквибб Компани |
Антитела к ox40 и их применение
|